Levy Nitzan, Tatomer Dierdre, Herber Candice B, Zhao Xiaoyue, Tang Hui, Sargeant Toby, Ball Lonnele J, Summers Jonathan, Speed Terence P, Leitman Dale C
Department of Obstetrics, Center for Reproductive Sciences, Cellular and Molecular Pharmacology, University of California-San Francisco, San Francisco, CA 94143-0556, USA.
Mol Endocrinol. 2008 Feb;22(2):287-303. doi: 10.1210/me.2007-0340. Epub 2007 Oct 25.
Estrogen receptors (ERs) regulate gene transcription by interacting with regulatory elements. Most information regarding how ER activates genes has come from studies using a small set of target genes or simple consensus sequences such as estrogen response element, activator protein 1, and Sp1 elements. However, these elements cannot explain the differences in gene regulation patterns and clinical effects observed with estradiol (E(2)) and selective estrogen receptor modulators. To obtain a greater understanding of how E(2) and selective estrogen receptor modulators differentially regulate genes, it is necessary to investigate their action on a more comprehensive set of native regulatory elements derived from ER target genes. Here we used chromatin immunoprecipitation-cloning and sequencing to isolate 173 regulatory elements associated with ERalpha. Most elements were found in the introns (38%) and regions greater than 10 kb upstream of the transcription initiation site (38%); 24% of the elements were found in the proximal promoter region (<10 kb). Only 11% of the elements contained a classical estrogen response element; 23% of the elements did not have any known response elements, including one derived from the naked cuticle homolog gene, which was associated with the recruitment of p160 coactivators. Transfection studies found that 80% of the 173 elements were regulated by E(2), raloxifene, or tamoxifen with ERalpha or ERbeta. Tamoxifen was more effective than raloxifene at activating the elements with ERalpha, whereas raloxifene was superior with ERbeta. Our findings demonstrate that E(2), tamoxifen, and raloxifene differentially regulate native ER-regulatory elements isolated by chromatin immunoprecipitation with ERalpha and ERbeta.
雌激素受体(ERs)通过与调控元件相互作用来调节基因转录。关于ER如何激活基因的大多数信息来自于使用一小部分靶基因或简单共有序列(如雌激素反应元件、激活蛋白1和Sp1元件)的研究。然而,这些元件无法解释雌二醇(E₂)和选择性雌激素受体调节剂所观察到的基因调控模式和临床效应的差异。为了更深入地了解E₂和选择性雌激素受体调节剂如何差异调节基因,有必要研究它们对源自ER靶基因的更全面的天然调控元件的作用。在这里,我们使用染色质免疫沉淀-克隆和测序来分离与ERα相关的173个调控元件。大多数元件位于内含子(38%)和转录起始位点上游大于10 kb的区域(38%);24%的元件位于近端启动子区域(<10 kb)。只有11%的元件包含经典的雌激素反应元件;23%的元件没有任何已知的反应元件,包括一个源自裸表皮同源基因的元件,该元件与p160共激活因子的募集有关。转染研究发现,173个元件中的80%受E₂、雷洛昔芬或他莫昔芬与ERα或ERβ的调控。他莫昔芬在用ERα激活元件方面比雷洛昔芬更有效,而雷洛昔芬在用ERβ时更具优势。我们的研究结果表明,E₂、他莫昔芬和雷洛昔芬对通过与ERα和ERβ进行染色质免疫沉淀分离的天然ER调控元件有差异调节作用。